intetumumab

{{Short description|Monoclonal antibody}}

{{Drugbox

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 458270895

| type = mab

| image =

| alt =

| mab_type = mab

| source = u

| target = integrin alpha-V

| tradename =

| Drugs.com =

| MedlinePlus =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category=

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 725735-28-4

| ATC_prefix = none

| ATC_suffix =

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = GQE1BJE2NI

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| KEGG = D09631

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| C=6468 | H=10008 | N=1744 | O=2006 | S=40

}}

Intetumumab is a human monoclonal antibody targeting integrins{{cite journal | vauthors = Łasiñska I, Mackiewicz J | title = Integrins as A New Target for Cancer Treatment | journal = Anti-Cancer Agents in Medicinal Chemistry | volume = 19 | issue = 5 | pages = 580–586 | date = 2019 | pmid = 30451118 | doi = 10.2174/1871520618666181119103413 | s2cid = 53952455 }} that was being studied for the treatment of solid tumors.{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Intetumumab|publisher=American Medical Association|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/intetumumab.pdf}}

Intetumumab was developed by Centocor, Inc.

Phase II clinical trials for treatment of melanoma and prostate cancer were in progress when development of the drug was discontinued.{{cite web|title=Intetumumab|url=http://adisinsight.springer.com/drugs/800019252|website=AdisInsight|access-date=30 January 2017}}